Merck + Co., Inc.

Rhythm Pharmaceuticals, Inc.

Deuterx, LLC

Other

Charité – Universitätsmedizin Berlin

Yao the Bard, LLC

Leonardus H T Van Der Ploeg

Bart Henderson

Andrew D Howard

Shubh D Sharma

Arthur A Patchett

Ravi P Nargund

Raman Kumar Bakshi

Zhixiong Ye

Douglas J MacNeil

Hui Zheng

Brenda L Palucki

Howard Y Chen

Louis Anthony Tartaglia

Kevin R Lynch

Vincent Jacques

Sheila DeWitt

Scott D Feighner

Roy G Smith

Tung M Fong

David H Weinberg

Airu S Chen

Paul A Liberator

Doris F Cully

Ping Jiang

Jeffrey W Warmke

Carina P Tan

Qingyun Liu

David L Williams

Margaret A Cascieri

Joseph P Arena

Iyassu K Sebhat

Michael R Tota

Sangram S Sisodia

Khaled J Barakat

Ruey-Ruey C Huang

Kathleen A Sullivan

Karen Kulju McKee

Sheng-Shung Pong

Myrna E Trumbauer

Jie Liu

Tong M Fong

James M Schaeffer

Peter Kuhnen

Prashant G Trivedi

Hong Yu

Xiaoming Guan

Michael M Jiang

Su Qian

Philip Chun-Ying Wong

Lee-Yuh Pai

Robert P Heavens

Gurparlash Singh

David W Smith

Theodore N Mellin

Dalip J S Sirinathsinghji

Alison Strack

Aurawan Vongs

Ruiping Wang

Halley Young

Qingping Jiang

The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

Pharmaceutical compositions

The disclosure is related to a method of treating a disorder, such as Prader Willi Syndrome (PWS), obesity or hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. Also described is method of treating a subject having a deficiency in the pro-opiomelanocortin (POMC)-MC4R pathway, such as a POMC-null or a PCSK-null subject, using a MC4R agonist.

Method of treating melanocortin-4 receptor pathway-associated disorders

The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.

Peptide compositions

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to &#x3b1;-melanocortin stimulating hormone (&#x3b1;-MSH).

Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

Described herein are real-time musical translation devices (RETM) and methods of use thereof. Exemplary uses of RETMs include optimizing the understanding and/or recall of an input message for a user and improving a cognitive process in a user.

Systems and methods for transposing spoken or textual input to music

The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.

Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone

The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.

Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding the melcanocortin-3 receptor protein (MC-3R). MC-3R deficient transgenic animals have increased fatmass and reduced lean body mass, showing that the MC-3R protein is involved in the regulation of body fat and muscle mass. These MC-3R deficient transgenic animals can be used to select for and test potential modulators of MC-3R. This data allows for methods of screening for MC-3R modulators which effect body weight and associated methods of treating various disorders associated with inappropriate regulation of body weight. The disclosure also relates to a MC-3R/MC-4R double knockout mouse which can be used to select for and test potential modulators (e.g., agonists or antagonists) of MC-3R and/or MC-4R. It is shown that MC-3R serves a non-redundant role, when compared to MC-4R, in the regulation of energy homeostasis.

Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight

A new neuromedin U receptor, designated NMUR2 has been found, which is involved in modulation of feeding behavior in mammals. Ligands of this receptor are able to modulate eating, and weight gain. Amino acid sequences of the human and rat forms, as well as their nucleic acid sequences are given.

Neuromedin U receptor NMUR2 and nucleotides encoding it

The present invention relates to rhesus monkey DNA molecules encoding the melanocortin-4 receptor protein, recombinant vectors comprising DNA molecules encoding rhesus MC-4R, recombinant host cells which contain a recombinant vectors encoding rhesus MC-4R, the rhesus MC-4R protein encoded by the DNA molecule, and methods of identifying selective agonists and antagonists of rhesus MC-4R.

DNA molecules encoding the melanocortin 4 receptor protein from rhesus monkey

Growing community of inventors

Scotch Plains, NJ, United States of America

Leonardus H T Van Der Ploeg